HYDERABAD: World’s first intranasal Covid-19 vaccine approved for emergency use (EUA), India’s drug regulator on Tuesday approved Bharat . BiotechnologyIntranasal vaccine BBV154 is intended for primary immunization of persons 18 years of age and older.
The Central Drug Standards Control Organization (CDSCO) approved for limited emergency use BBV154, Union Health Minister Dr. Mansukh Mandaviya announced via a tweet on Tuesday.
The Central Drug Standards Control Organization (CDSCO) approved for limited emergency use BBV154, Union Health Minister Dr. Mansukh Mandaviya announced via a tweet on Tuesday.
“Big boost to India’s fight against COVID-19! Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Adenovirus vaccine) recombinant nasal vaccine has been approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in the 18+ age group to limit use in emergency situations,” the minister tweeted. This move will further strengthen the collective fight against the pandemic. “India has harnessed its science, R&D and human resources in the fight against COVID-19 under the leadership of PM @NarendraModi Ji. With a science-based approach & Sabka Prayas, we will defeat COVID-19,” he added.
